Johnson & Johnson has dropped a pair of CAR-T cell therapies, axing programs it once predicted could deliver peak sales north ...

Cytotoxic T lymphocytes are the body's specialized "killer" cells, precisely eliminating infected or cancerous cells. Their ...

The peripheral T-cell lymphoma treatment market is witnessing steady growth, primarily driven by the increasing incidence, leading to an increased patient population, which fuels the ongoing treatment ...

The body’s “killer” T cells don’t just attack—they strike with astonishing precision, forming a tiny, highly organized ...

Rising incidence rates and innovation in immunotherapy drive an 8.66% CAGR from 2026 to 2035.Austin, United States, April 23, 2026 (GLOBE NEWSWIRE) -- According to SNS Insider, The T-cell Lymphoma ...

While rare, secondary cancers after CAR T-cell therapy have been reported, leading the FDA to mandate boxed warnings on all approved therapies. In a first, targeted therapy was used to treat a T-cell ...

Following his cancer-free announcement Sam Neill highlights the need to make immunotherapy accessible to more people globally ...

Relapsed/refractory peripheral and cutaneous T-cell lymphomas (R/R PTCL and CTCL) are aggressive blood cancers that often resist standard therapy. Patients with these lymphomas may require stem cell ...

Sam Neill has revealed that he is now cancer-free. The actor was told his initial treatment wouldn't work longterm. Then, he ...

Please provide your email address to receive an email when new articles are posted on . Most patients with B-cell lymphomas who relapsed after CAR T-cell therapy responded to the novel, ...